No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 5, 2013, Pages 572-577

  Souda, Sajini ^a,b   Gaseitsiwe, Simani ^a   Georgette, Nathan ^c   Powis, Kathleen ^a,d,e   Moremedi, Daisy ^a   Iketleng, Thato ^a   Leidner, Jean ^e   Moffat, Claire ^a   Ogwu, Anthony ^a   Lockman, Shahin ^a,e,f   Moyo, Sikhulile ^a   Mmalane, Mompati ^a   Musonda, Rosemary ^a   Makhema, Joseph ^a   Essex, Max ^a,e   Shapiro, Roger ^a,e,g  

^a BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^b UNIVERSITY OF BOTSWANA   (Botswana)

^c HARVARD UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Botswana; Highly active antiretroviral therapy; Minor drug resistance mutations; Mother to child HIV transmission

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS LOPINAVIR PLUS RITONAVIR PLUS ZIDOVUDINE; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BOTSWANA; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; TREATMENT WITHDRAWAL; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BOTSWANA; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PREGNANCY; SEQUENCE ANALYSIS, DNA; WITHHOLDING TREATMENT;

EID: 84883363255     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31829308f8     Document Type: Article

References (57)

1. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. 2010 Revision. Geneva, Switzerland: World Health Organization; 2010.
2. El-Sadr W, Lundgren JD, Neaton J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
3. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet. 2006;367: 1981-1989.
4. Pogány K, Vanvalkengoed IG, Prins JM, et al. Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). J Acquir Immune Defic Syndr. 2007;44:395.
5. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007; 21:965.
6. Salmon D, Daniel N, Krivine A. Viral rebound and risk of emergence of resistant strains after HAART interruption in HIV chronically infected patients (pts) with undetectable viremia. Paper presented at: The XIV International AIDS Conference: AIDS 2002; July 7-12, 2002, Barcelona, Spain. Abstract: WePeB5892.
7. Pilotto JH, Grinsztejn B, Veloso V, et al. High emergence of drug resistance after HAART interruption at delivery in a cohort of HIV+ pregnant women submitted to antiretroviral treatment to prevent mother-to-child transmission in Rio de Janeiro, Brazil. Retrovirology. 2009;6(suppl 1):O14.
8. Hauser A, Mugenyi K, Kabasinguzi R, et al. Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis. PLoS One. 2011;6:e20357.
9. Soto-Ramirez LE, Rodriguez-Diaz R, Durán AS, et al. Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs. AIDS Res Hum Retroviruses. 2008;24:797-804.
10. Lehman DA, Chung MH, Mabuka JM, et al. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr. 2009;51:522.
11. Pérez H, Vignoles M, Laufer N, et al. Short communication low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen. Antivir Ther. 2008;13:135-139.
12. Chokephaibulkit K, Chaisilwattana P, Vanprapar N, et al. Lack of resistant mutation development after receiving short-course zidovudine plus lamivudine to prevent mother-to-child transmission. AIDS. 2005;19:1231.
13. Gingelmaier A, Eberle J, Kost BP, et al. Protease inhibitor-based antiretroviral prophylaxis during pregnancy and the development of drug resistance. Clin Infect Dis. 2010;50:890.
14. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362: 2282-2294. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20554983. Accessed March 20, 2011. [Multicenter StudyRandomized Controlled Trial Research Support, N.I.H., Extramural].
15. Wallis CL, Papathanasopoulos MA, Lakhi S, et al. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods. 2010;163:505-508.
16. Bussmann H, Novitsky V, Wester W, et al. HIV-1 subtype C drugresistance background among ARV-naive adults in Botswana. Antivir Chem Chemother. 2005;16:103-115.
17. Stanford University HIV Drug Resistance Database. Available at http://hivdb.stanford.edu. Accessed July 1, 2011.
18. Shafer R, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007;21:215.
19. HamersRL, Wallis CL,Kityo C, et al.HIV-1 drug resistance in antiretroviralnaive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011;11: 750-759.
20. Kandathil A, Kannangai R, Abraham O, et al. Genotypic resistance profile of HIV-1 protease gene: a preliminary report from Vellore, South India. Indian J Med Microbiol. 2008;26:151.
21. Bakhouch K, Oulad-Lahcen A, Bensghir R, et al. The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naive (HIV1)-infected individuals in Casablanca, Morocco. J Infect Dev Ctries. 2009;3:380-391.
22. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356:135-147.
23. Lyons FE, Coughlan S, Byrne CM, et al. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS. 2005;19:63.
24. Duran AS, Losso MH, Salomón H, et al. Drug resistance among HIVinfected pregnant women receiving antiretrovirals for prophylaxis. AIDS. 2007;21:199.
25. Ellis GM, Huang S, Hitti J, et al. Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum. J Acquir Immune Defic Syndr. 2011;58:241.
26. Paredes R, Cheng I, Kuritzkes DR, et al. Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. AIDS. 2010;24:45.
27. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
28. Ait-Khaled M, Rakik A, Griffin P, et al. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy. Antivir Ther. 2002; 7:43-51.
29. Nolan M, Fowler MG, Mofenson LM. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J Acquir Immune Defic Syndr. 2002;30:216.
30. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-1861.
31. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265-272.
32. Melby T, Tortell S, Thorborn D. Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients on failing ABC/COM. Paper presented at: 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, IL.
33. Lange J, Hill A, Ait-Khaled M, et al. Does the M184V mutation affect the efficacy of HAART? Evidence from sequential addition of protease inhibitors or abacavir to zidovudine/lamivudine or stavudine/lamivudine. Poster presented at: 7th European Conference on Clinical Aspects and Treatment of HIV Infection; October 23-27, 1999; Lisbon, Portugal. Poster 384.
34. García F, Plana M, Ortiz GM, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS. 2001;15:F29.
35. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a doubleblind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51-60.
36. Taylor S, Boffito M, Khoo S, et al. Stopping antiretroviral therapy. AIDS. 2007;21:1673.
37. Lange J, Goudsmit J, Weverling G. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002; 359:1178-1186.
38. Stretcher BN, Pesce AJ, Frame PT, et al. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1994;38:1541-1547.
39. Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother. 2004;48:176-182.
40. Ford J, Cornforth D, Hoggard PG, et al. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. Antivir Ther. 2004;9:77-84.
41. Boehringer Ingelheim Ltd. Viramune® (nevirapine). Summary of Product Characteristics. Updated July 19, 2011. Available from http://emc. medicines.org.uk/medicine/322/SPC/Viramune%20Tablets/. Accessed December 1, 2011.
42. Piliero P, Shachoy-Clark AD, Para M, et al. A study examining the pharmacokinetics of abacavir and the intracellular carbovir triphosphate (GSK Protocol CNA10905). In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. September 14-17, 2003, Chicago, Illinois.
43. Kaletra® (lopinavir/ritonavir). Summary of product characteristics, 2004. Abbott Laboratories. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000368/WC500039043.pdf. Accessed December 1, 2011.
44. Metzner KJ, Giulieri SG, Knoepfel SA, et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and adherent patients. Clin Infect Dis. 2009;48:239-247.
45. Metzner K, Rauch P, Von Wyl V, et al. Prevalence of minority quasispecies of drug-resistant HIV-1 in patients with primary HIV-1 infection in Zurich in the years 2002-2006. Antivir Ther. 2007;12:47.
46. Peuchant O, Thiébaut R, Capdepont S, et al. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS. 2008;22:1417.
47. Cane PA. New developments in HIV drug resistance. J Antimicrob Chemother. 2009;64(suppl 1):i37-i40.
48. MacLeod IJ, Rowley CF, Thior I, et al.Minor resistant variants in nevirapineexposed infants may predict virologic failure on nevirapine-containing ART. J Clin Virol. 2010;48:162-167.
49. Giuliano M, Palmisano L, Galluzzo CM, et al. Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission. AIDS. 2003;17:1570.
50. Church JD, Hudelson SE, Guay LA, et al. Short communication: HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes a, C, and D. AIDS Res Hum Retroviruses. 2007;23:764-768.
51. Coovadia A, Hunt G, Abrams EJ, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009;48:462-472.
52. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008;5:e158.
53. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure. JAMA. 2011;305:1327.
54. Charpentier C, Dwyer DE, Mammano F, et al. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol. 2004;78:4234-4247.
55. Metzner KJ, Rauch P, von Wyl V, et al. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis. 2010;201:1063-1071.
56. Ruiz L, Martinez-Picado J, Romeu J, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS. 2000;14:397-403.
57. Harrigan PR, Hogg RS, Dong WWY, et al. Predictors of HIV drugresistance mutations in a large antiretroviral-naïve cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-347.